化疗后的免疫学修改与卵巢癌的延迟复发有关
Nicholas Adzibolosu1,2, Ayesha B Alvero1,3, Rouba Ali-Fehmi1,3
1C. S. Mott Center for Human Growth and Development, Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, United States.
Frontiers in immunology
|July 12, 2023
概括
化疗对高度严重卵巢癌 (HGSOC) 患者的瘤免疫微环境的影响不同. 晚期复发的瘤显示出逆转的前瘤免疫力,与早期复发的瘤不同,提供了新的生存策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
背景情况:
- 高度血清性卵巢癌 (HGSOC) 在标准化疗后经常复发.
- 了解影响复发模式的因素对于改善患者存活率至关重要.
- 瘤微环境在化疗反应和复发中的作用尚未完全理解.
研究的目的:
- 研究早期和晚期HGSOC复发之间的基因表达和瘤免疫微环境的差异.
- 识别与化疗反应和复发时间相关的分子特征.
主要方法:
- 从24名HGSOC患者的配对瘤样本 (化疗前和后) 的转录组分析.
- 生物信息分析包括基因本体学,途径分析和免疫细胞分数归算 (CIBERSORTx).
- 早期和晚期复发组之间的分子概况的比较,以及化疗前后样本之间的比较.
主要成果:
- 在早期和晚期复发瘤之间没有观察到显著的化疗前差异.
- 化疗在晚期复发瘤中诱导了显著的免疫变化,但在早期复发瘤中没有.
- 一个关键的发现是,在晚期复发患者的化学疗法后,前瘤免疫特征的逆转.
结论:
- 这项研究是首次将化疗诱导的免疫学修饰与卵巢癌复发时间联系起来.
- 研究结果表明,免疫微环境对化疗的反应是复发模式的关键决定因素.
- 这些见解提供了潜在的新治疗点,以提高HGSOC患者的生存率.
更多相关视频
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
2.7K
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
18.3K
相关概念视频
01:27Tumor Immunotherapy
567
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
567
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K